# Comprehensive Literature Search Strategy
## Type 2 Diabetes Drug Sequencing Network Meta-Analysis

### Search Objective
To identify all randomized controlled trials and relevant observational studies evaluating the comparative effectiveness of diabetes medication classes and combinations for optimizing HbA1c, cardiovascular, renal, hypoglycemia, and weight outcomes in adults with type 2 diabetes.

### Target Databases
- **Primary**: PubMed, CENTRAL (Cochrane Central Register of Controlled Trials)
- **Secondary**: ClinicalTrials.gov, Embase, Web of Science
- **Regulatory**: FDA/EMA drug approval documents, regulatory clinical study reports

### Search Timeline
- **Start date**: No date restriction (comprehensive search)
- **End date**: Search completion date
- **Update frequency**: Monthly monitoring for new publications

## Population Search Terms
**Primary Population**: Adults with type 2 diabetes mellitus

### Core Population Terms
```
("type 2 diabetes" OR "type 2 diabetic" OR "T2DM" OR "T2D" OR "non-insulin dependent diabetes" OR "adult-onset diabetes")
```

### Population Modifiers
```
AND ("adult" OR "adults" OR "elderly" OR "older adult" OR "geriatric" OR "senior" OR "aged")
AND (metformin OR "treatment-naïve" OR "newly diagnosed" OR "drug-naïve")
```

## Intervention Search Terms
**Drug Classes**: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, Thiazolidinediones, Basal insulin, Prandial insulin, Dual therapy, Triple therapy

### SGLT2 Inhibitors
```
("SGLT2 inhibitor" OR "SGLT2i" OR "sodium-glucose cotransporter 2" OR canagliflozin OR dapagliflozin OR empagliflozin OR ertugliflozin OR sotagliflozin OR bexagliflozin)
```

### GLP-1 Receptor Agonists
```
("GLP-1 receptor agonist" OR "GLP-1RA" OR "glucagon-like peptide-1" OR liraglutide OR semaglutide OR dulaglutide OR exenatide OR lixisenatide OR albiglutide OR tirzepatide OR retatrutide)
```

### DPP-4 Inhibitors
```
("DPP-4 inhibitor" OR "DPP-4i" OR "dipeptidyl peptidase-4" OR sitagliptin OR saxagliptin OR linagliptin OR alogliptin OR vildagliptin OR gemigliptin)
```

### Thiazolidinediones
```
("thiazolidinedione" OR "TZD" OR pioglitazone OR rosiglitazone OR troglitazone)
```

### Insulin Therapies
```
("basal insulin" OR "long-acting insulin" OR glargine OR detemir OR degludec OR "prandial insulin" OR "short-acting insulin" OR "rapid-acting insulin" OR lispro OR aspart OR glulisine)
```

### Combination Therapies
```
("dual therapy" OR "triple therapy" OR "combination therapy" OR "add-on therapy" OR "sequential therapy")
```

## Outcome Search Terms
**Primary Outcomes**: Composite CV outcomes, eGFR decline, ESKD, Severe hypoglycemia
**Secondary Outcomes**: HbA1c change, Weight change, Individual CV events

### Cardiovascular Outcomes
```
("cardiovascular outcome" OR "CV outcome" OR "MACE" OR "major adverse cardiovascular event" OR "myocardial infarction" OR "MI" OR "stroke" OR "cardiovascular death" OR "CV death" OR "heart failure" OR "HF" OR "hospitalization for heart failure")
```

### Renal Outcomes
```
("renal outcome" OR "kidney outcome" OR "eGFR decline" OR "estimated glomerular filtration rate" OR "ESKD" OR "end-stage kidney disease" OR "ESRD" OR "end-stage renal disease" OR "kidney failure" OR "renal failure" OR "albuminuria" OR "proteinuria" OR "chronic kidney disease" OR "CKD")
```

### Glycemic Outcomes
```
("HbA1c" OR "glycated hemoglobin" OR "hemoglobin A1c" OR "hypoglycemia" OR "hypoglycaemia" OR "severe hypoglycemia" OR "severe hypoglycaemia" OR "blood glucose" OR "glycemic control")
```

### Weight Outcomes
```
("body weight" OR "weight change" OR "weight loss" OR "weight gain" OR "BMI" OR "body mass index")
```

## Moderator Variables Search Terms
```
("baseline ASCVD" OR "established cardiovascular disease" OR "cardiovascular disease history" OR "baseline CKD" OR "chronic kidney disease" OR "baseline HF" OR "heart failure" OR "baseline BMI" OR "body mass index" OR "diabetes duration" OR "disease duration")
```

## Complete Search Strategy by Database

### PubMed Search Strategy
```
# Line 1: Population
("type 2 diabetes mellitus"[TIAB] OR "type 2 diabetic"[TIAB] OR T2DM[TIAB] OR T2D[TIAB] OR "non-insulin dependent diabetes"[TIAB] OR "adult-onset diabetes"[TIAB])

# Line 2: Interventions
("SGLT2 inhibitor"[TIAB] OR SGLT2i[TIAB] OR canagliflozin[TIAB] OR dapagliflozin[TIAB] OR empagliflozin[TIAB] OR ertugliflozin[TIAB] OR GLP-1[TIAB] OR liraglutide[TIAB] OR semaglutide[TIAB] OR dulaglutide[TIAB] OR DPP-4[TIAB] OR sitagliptin[TIAB] OR saxagliptin[TIAB] OR linagliptin[TIAB] OR pioglitazone[TIAB] OR rosiglitazone[TIAB] OR "basal insulin"[TIAB] OR glargine[TIAB] OR detemir[TIAB] OR degludec[TIAB])

# Line 3: Study Design
(randomized[TIAB] OR randomised[TIAB] OR RCT[TIAB] OR "controlled trial"[TIAB] OR "clinical trial"[TIAB])

# Line 4: Outcomes
("cardiovascular outcome"[TIAB] OR MACE[TIAB] OR "HbA1c"[TIAB] OR hypoglycemia[TIAB] OR hypoglycaemia[TIAB] OR "kidney function"[TIAB] OR eGFR[TIAB])

# Combined Strategy
(#1 AND #2 AND #3 AND #4)
```

### CENTRAL (Cochrane) Search Strategy
```
# Population
type-2-diabetes OR T2DM OR T2D

# Interventions
SGLT2 OR GLP-1 OR DPP-4 OR thiazolidinedione OR insulin

# Study Design
randomi* OR trial OR RCT

# Combined
Population AND Interventions AND Study Design
```

### ClinicalTrials.gov Search Strategy
**Advanced Search Filters:**
- Study type: Interventional Studies
- Conditions: Diabetes Mellitus, Type 2
- Interventions: SGLT2, GLP-1, DPP-4, Thiazolidinediones, Insulin
- Phases: Phase 2, Phase 3, Phase 4
- Enrollment: ≥100 participants
- Study Status: Completed, with results

## Inclusion Criteria

### Study Design
- Randomized controlled trials (RCTs)
- Cluster RCTs with appropriate analysis
- Multi-arm RCTs comparing multiple interventions
- Large observational studies (n ≥ 500) for long-term outcomes

### Population
- Adults (≥18 years) with type 2 diabetes mellitus
- On metformin monotherapy or treatment-naïve
- Mixed populations acceptable if ≥80% T2DM

### Interventions
- SGLT2 inhibitors (as monotherapy or add-on)
- GLP-1 receptor agonists (as monotherapy or add-on)
- DPP-4 inhibitors (as monotherapy or add-on)
- Thiazolidinediones (as monotherapy or add-on)
- Basal insulin (as monotherapy or add-on)
- Prandial insulin (as monotherapy or add-on)
- Dual therapy combinations
- Triple therapy combinations

### Comparators
- Placebo
- Active comparators from specified drug classes
- Standard care or metformin monotherapy

### Outcomes
**Primary Outcomes:**
- Composite cardiovascular outcomes (MACE-3 or MACE-4)
- eGFR decline (≥40% or ≥50% decline)
- End-stage kidney disease (ESKD)
- Severe hypoglycemia

**Secondary Outcomes:**
- HbA1c change from baseline
- Weight change from baseline
- Individual CV events (MI, stroke, CV death)
- All-cause mortality

### Follow-up Duration
- Minimum 12 weeks for glycemic outcomes
- Minimum 12 months for cardiovascular/renal outcomes
- No maximum follow-up restriction

## Exclusion Criteria

### Study Design
- Non-randomized studies (except large observational studies for long-term outcomes)
- Single-arm studies
- Crossover trials without adequate washout
- Trials with <50 participants per arm

### Population
- Type 1 diabetes mellitus
- Gestational diabetes
- Pediatric populations (<18 years)
- Prediabetes or other glucose metabolism disorders

### Interventions
- Investigational drugs not approved in major markets
- Non-standard dosing regimens
- Combination therapies not reflecting clinical practice

### Outcomes
- Surrogate outcomes only (without patient-important outcomes)
- Insufficient outcome data for analysis
- Outcomes reported only in figures (without numerical data)

## Search Process Documentation

### Search Execution
1. **Initial Search**: Execute comprehensive search across all databases
2. **Deduplication**: Remove duplicate records using reference management software
3. **Title/Abstract Screening**: Two independent reviewers
4. **Full-text Review**: Two independent reviewers with arbitration
5. **Data Extraction**: Standardized forms with double extraction
6. **Quality Assessment**: Cochrane Risk of Bias tool for RCTs

### Search Update Protocol
- **Monthly Alerts**: Set up automated alerts in PubMed and ClinicalTrials.gov
- **Quarterly Review**: Comprehensive search update every 3 months
- **Pre-submission Update**: Final search update before manuscript submission
- **Living Review**: Consider updating for 12 months post-publication

### Documentation Requirements
- Complete search strategies for each database
- Number of results at each stage (PRISMA flow)
- Inclusion/exclusion decisions with reasons
- Kappa statistics for inter-rater agreement
- Search execution dates and personnel

## Quality Assurance Measures

### Search Sensitivity
- Test search strategy against known relevant studies
- Ensure all major CVOTs are captured
- Validate against recent systematic reviews

### Screening Reliability
- Pilot screening on 50 articles for training
- Calculate inter-rater agreement (Kappa > 0.8 target)
- Regular calibration meetings for reviewers

### Data Extraction Quality
- Standardized extraction forms
- Double independent extraction
- Discrepancy resolution protocols
- Regular quality checks

## References for Search Methodology
- Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2023.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement. BMJ. 2021.
- Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Ann Intern Med. 2017.

*Last updated: [Current Date]*
*Search conducted by: [Research Team]*
